|
| Wednesday, 13 June 2018, 10:20 HKT/SGT | |
| |  | |
Source: Fujitsu Ltd | |
|
|
|
|
| Use IT-based drug discovery to develop effective compounds |
TOKYO, June 13, 2018 - (JCN Newswire) - The University of Tokyo's Research Center for Advanced Science and Technology (RCAST), Fujitsu Limited, and Kowa Company Ltd. today announced that using IT-based drug discovery technologies, which entails computer-based virtual design and evaluation, they have successfully created new small molecule compounds that can inhibit cancer-causing "target proteins," and that demonstrate promise against cancers that have shown resistance to existing drugs. In order to link the results of this research to the creation of new drugs, Kowa intends to improve upon the small molecule compounds discovered through this research.
Details of the Research and the Division of Responsibilities
Fujitsu and RCAST began joint research on IT-based drug discovery in June 2011, with Kowa joining in July, conducting research projects around multiple drug discovery targets. This particular joint research project began in December 2015, selecting a drug-resistant oncogenic protein as a drug discovery target. Fujitsu used IT-based drug discovery to design a small molecule compound that featured inhibitory activity(1), and then Kowa synthesized the compound and assessed its inhibitory activity in experiments. RCAST took on the role of providing information on drug discovery targets based from a medical perspective. Fujitsu and Fujitsu Laboratories Ltd. additionally made repeated improvements to the IT-based drug discovery technologies during the course of the joint research project, increasing both accuracy and performance.
Results of the Joint Research
In this joint research, Fujitsu leveraged its proprietary technologies to provide Kowa with chemical structures with the anticipated effect of decreasing the activities of the target protein. Specifically, Fujitsu incorporated drug candidate compound design technology(2) and the drug discovery insights it has previously accumulated, and designed synthetic accessible small molecule compounds using computers. Next, the binding affinity of each compound with the target protein is calculated to narrow down the selection using the M2BAR method(3), which is an improvement on high precision activity prediction technology(4). Fujitsu also took into consideration the results of high precision conformational analysis(5) based on quantum mechanics. Kowa synthesized the small molecule compounds designed by Fujitsu, and confirmed that some of the compounds demonstrated the inhibitory activity desired for drug candidates. Kowa subsequently synthesized multiple small molecule compounds sharing similar chemical structures, and confirmed that a series of the synthesized compounds also showed inhibitory activity. Kowa is currently evaluating the complex structure of these compounds using X-ray crystallography, and plans to optimize the small molecule compounds obtained from this research to reflect the results to the discovery of new drugs. Through this joint research project, RCAST, Fujitsu, and Kowa have succeeded in using IT-based drug discovery to create new small molecule compounds with inhibitory activity against cancer-causing target proteins, and may one day prove effective even against cancers that show resistance to existing drugs.
(1) Inhibitory activity The degree to which a compound binds to a protein thought to cause a specific disease indication and inhibits the function of the protein. Usually expressed in terms of the concentration of the compound.
(2) Drug candidate compound design technology Optimum Packing of Molecular Fragments (OPMF), a software module developed by Fujitsu that designs small molecule compounds that bind to the functional site of proteins that are believed to cause specific disease indications and inhibit the activity of the proteins.
(3) M2BAR A computational method developed by Fujitsu Laboratories for rapidly and accurately predicting the quantitative activity of a compound using multiple binding patterns.
(4) High-precision activity prediction technology Software developed by Fujitsu Laboratories, comprised of MAPLECAFEE, a module that, based on molecular dynamics calculations, predicts the inhibitory activity of drug candidate compounds with a high level of precision that is equivalent to that of biochemical assays, and Force Field Formulator for Organic Molecules (FF-FOM), a module that generates highly detailed parameters for calculating the forces between atoms.
(5) Conformational analysis A method of analyzing the relationship between a compound's conformation (three-dimensional structure) and its potential energy.
About Research Center for Advanced Science and Technology
Research Center for Advanced Science and Technology (RCAST) aims to contribute to the development of science and technology by expeditiously taking on new challenges arising from the advancement of science and coincident changes in society, and by exploring new areas of advanced science and technology for the benefit of humankind and society. Find out more at http://www.rcast.u-tokyo.ac.jp.
About Kowa
Kowa Company, Ltd. is a private multinational company headquartered in Nagoya, Japan. Established in 1894, Kowa has been actively engaging in multidiscipline business including pharmaceuticals, textiles, machinery, and construction material fields. Its pharmaceutical division is focused on research and development for cardiovascular therapeutics, ophthalmology and anti-inflammatory agents. For more information, please see http://www.kowa.co.jp/eng.
Contact:
Research Center for Advanced Science and Technology, The University of Tokyo
Public Relations Ikuko Murayama
E-mail: press@rcast.u-tokyo.ac.jp
Fujitsu Limited
Public and Investor Relations
Tel: +81-3-3215-5259
URL: www.fujitsu.com/global/news/contacts/
Topic: Press release summary
Source: Fujitsu Ltd
Sectors: Enterprise IT, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Fujitsu Ltd |
| Mar 3, 2026 20:00 HKT/SGT |
|
Fujitsu and BCN Port Innovation Foundation leverage ocean digital twin technology to drive the regeneration of the Port of Barcelona |
| Mar 2, 2026 10:55 HKT/SGT |
|
Fujitsu supports sustainable growth for retailers with data and AI through Uvance for Retail |
| Feb 27, 2026 11:03 HKT/SGT |
|
Fujitsu POS solution enhances customer experience at Hankyu Hanshin Department Stores |
| Feb 25, 2026 11:00 HKT/SGT |
|
Beisia Automates Supermarket Refrigerator Temperature Monitoring and Recording with Fujitsu's IoT Visualization Solution |
| Feb 24, 2026 10:23 HKT/SGT |
|
Fujitsu expands Uvance for Finance offerings to accelerate DX across financial sector |
| Feb 19, 2026 11:12 HKT/SGT |
|
Osaka Hospital launches project to safely utilize generative AI for healthcare workforce improvements |
| Feb 18, 2026 09:41 HKT/SGT |
|
Fujitsu named to FORTUNE Magazine's list of 'World's Most Admired Companie's for eighth year running |
| Feb 17, 2026 11:21 HKT/SGT |
|
Fujitsu automates entire software development lifecycle with new AI-Driven Software Development Platform |
| Feb 13, 2026 21:50 HKT/SGT |
|
Fujitsu and 1Finity to highlight latest network technologies and AI solutions at MWC Barcelona 2026 |
| Feb 13, 2026 21:33 HKT/SGT |
|
Fujitsu to present latest technologies for creating social and industrial value through fusion of AI and computing at India AI Impact Summit 2026 |
| More news >> |
 |
|
|
|
